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Abstract
Introduction Blood biomarkers have the potential to moni-
tor the severity of chronic heart failure (CHF). Studies cor-
relating repeated measurements of blood biomarkers with
repeatedly assessed New York Heart Association (NYHA)
class over a prolonged follow-up period, and concomitantly
investigating their associations with clinical endpoints, have
not yet been performed.
Methods Between 2011–2013, 263 CHF patients were in-
cluded. At inclusion and subsequently every 3 months, we
measured N-terminal pro-B-type natriuretic (NT-proBNP),
high-sensitivity troponin T (Hs-TnT) and C-reactive protein
(CRP), and assessed NYHA class. The primary endpoint
comprised heart failure hospitalisation, cardiovascular mor-
tality, cardiac transplantation or left ventricular assist device
implantation. Time-dependent Cox models were used.
Results Mean age was 67 ± 13 years, 72% were men and
27% were in NYHA class III–IV. We obtained 886 repeated
measures (median 3 [IQR 2–5] per patient). The primary
endpoint was reached in 41 patients during a median fol-
low-up of 1.0 [0.6–1.4] year. Repeatedly measured NT-
proBNP and Hs-TnT were significantly associated with re-
peatedly assessed NYHA class, whereas CRP was not (NT-
proBNP: β [95% CI]: 1.56 [1.17–2.06]ln(ng/l) increase per
Electronic supplementary material The online version of this
article (https://doi.org/10.1007/s12471-017-1040-x) contains
supplementary material, which is available to authorized users.
 I. Kardys
i.kardys@erasmusmc.nl
1 Department of Cardiology, Noordwest Ziekenhuisgroep,
Alkmaar, The Netherlands
2 Department of Cardiology, Erasmus Medical Centre,
Rotterdam, The Netherlands
point increase in NYHA class, p = 0.002; HsTNT: β [95%
CI]: 1.58 [1.21–2.07]). Serially measured NT-proBNP (HR
[95% CI]:2.86 [1.73–4.73]), CRP (1.69 [1.21–2.34]) and
NYHA class (2.33 [1.51–3.62]) were positively and inde-
pendently associated with the primary endpoint, whereas
Hs-TnT lost statistical significance after multivariable ad-
justment. A model containing serially measured NYHA
class and NT-proBNP displayed a C-index of 0.84, while
serially measured NYHA class and CRP showed a C-index
of 0.82.
Conclusion Temporal NT-proBNP, CRP and NYHA class
patterns are independently associated with adverse clinical
outcome. Serially measured NT-proBNP and NYHA class
are best suited for monitoring CHF outpatients.
Keywords Heart failure · Biomarkers · NYHA class ·
Repeated measurements
Introduction
Adjustment of medicinal treatment for chronic heart fail-
ure (CHF) requires considerable clinical acumen and may
in some cases cause misjudgement in risk assessment and
consequently suboptimal treatment [1–4]. Therefore, sev-
eral diagnostic tools have been developed over the past
decades which aim to objectify disease severity, such as
the New York Heart Association (NYHA) functional clas-
sification [1, 4], which has limited reproducibility and high
inter-observer variability [5]. Conversely, circulating blood
biomarkers are less subjective to interpretation, and have
the potential to monitor subtle changes in the heart that re-
flect and possibly predict adverse changes before they be-
come clinically apparent [6]. The use of biomarkers, such
as B-type natriuretic peptides (BNP), cardiac troponins and
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C-reactive protein (CRP), for risk stratification of CHF pa-
tients has already been demonstrated [7–13]. Moreover, al-
though trials on natriuretic peptide-guided therapy of HF
have provided somewhat inconsistent results [9, 14], natri-
uretic peptide-guided HF therapy has recently been given
a class IIa recommendation in American College of Cardiol-
ogy/American Heart Association HF guidelines to achieve
guideline-directed medical therapy [15, 16].
Several studies have previously examined NYHA class
in relation to clinical outcome in CHF patients. However,
these studies either used single, baseline assessments or two
repeated assessments taken in a relatively short time interval
[17, 18]. Furthermore, studies on the association between
blood biomarkers and NYHA class in CHF are scarce, and
studies assessing both these properties repeatedly are non-
existent. Finally, the predictive value of serially assessed
blood biomarkers and NYHA class scores for adverse clin-
ical outcome has never yet been compared in stable CHF
patients.
Therefore, the aim of the current investigation, per-
formed in 263 patients with CHF, was to examine the
associations between repeatedly measured NT-proBNP,
troponin T (Hs-TnT), CRP, and NYHA class, as well as the
associations of their temporal patterns with adverse clinical
outcome. Based on this, we evaluated the incremental value
of serially measuring blood biomarkers to clinical assess-
ment in terms of serial NYHA class scoring, for monitoring
stable CHF outpatients.
Methods
Patients
The Serial Biomarker Measurements and New Echocardio-
graphic Techniques in Chronic Heart Failure Patients Result
in Tailored Prediction of Prognosis (Bio-SHiFT) study was
designed to investigate the hypothesis that temporal pat-
terns of biomarkers involved in CHF are associated with
prognosis. Bio-SHiFT is an ongoing prospective, observa-
tional study of stable outpatients with CHF, conducted in
Erasmus MC, Rotterdam, the Netherlands and Noordwest
Ziekenhuisgroep, Alkmaar, the Netherlands. Patients were
recruited during their regular outpatient visits and were in
a clinically stable condition. Patients were eligible for in-
clusion if aged 18 years or older, capable of understanding
and signing informed consent, and if CHF (including HF
with preserved ejection fraction) was diagnosed ≥3 months
ago according to the guidelines of the European Society of
Cardiology (ESC) [1, 4, 19]. Detailed inclusion and exclu-
sion criteria are shown in Fig. 1. The study was approved
by the medical ethics committees of the participating hospi-
tals and was conducted in accordance with the Declaration
of Helsinki. Written informed consent was obtained from
all patients. The study is registered in ClinicalTrials.gov,
number NCT01851538. Follow-up for this analysis lasted
from October 2011 until November 2013.
Baseline assessment
At baseline, patients were evaluated by trained research
physicians, who collected information on HF-related symp-
toms, including NYHA class [1, 4]. History of chronic renal
failure was defined as a glomerular filtration rate less than
60 ml/min/1.73 m2. Alcohol consumption was defined as
drinking ≥1 alcoholic consumption per day. Electrocardio-
graphy and echocardiography were performed. Data were
entered into electronic case report forms. Non-fasting blood
and urine samples were collected.
Follow-up visits
Study follow-up visits were scheduled every 3 months
(a window of ±1 month was allowed), for a maximum of
30 months. At each tri-monthly study visit, a short medical
evaluation was performed, NYHA functional class was
scored and blood and urine samples were collected.
Blood sampling and biomarker measurement
Blood samples were collected at baseline and at each fol-
low-up visit, and were processed and stored locally at a tem-
perature of –80 °C within 2 h after blood collection. When
applicable, samples were transported to the central labora-
tory (Erasmus MC, Rotterdam, the Netherlands) under con-
trolled conditions (at a temperature of –80 °C), until batch
analysis was performed. Thus, the biomarker measurements
performed for this study did not lead to treatment adjust-
ments.
Batch analysis of NT-proBNP, Hs-TnT, and CRP was
performed in the Clinical Chemistry Laboratory of the
Erasmus MC. Plasma NT-proBNP and Hs-TnT were
analysed using electrochemiluminesence immunoassays
(Roche Diagnostics, Elecsys 2010, Indianapolis, Indiana,
USA). For NT-proBNP, concentrations were measured
ranging from 0.6 to 4130 pmol/l. Coefficients of vari-
ation (CVs) were <5% at mean values ranging from
5.19–274 pmol/l. For Hs-TnT, concentrations were mea-
sured ranging from 3–10,000 ng/l. CVs were <5% at mean
values ranging from 12.7–1,819 ng/l. CRP was measured
using an immunoturbidimetric assay (Roche Hitachi 912
chemistry analyser, Basel, Switzerland). This system mea-
sures concentrations ranging from 0.3 to 350 mg/l, and CVs
were <5% at mean values ranging from 0.84–284 mg/l.
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Fig. 1 Inclusion and exclusion criteria
Clinical study endpoints
During follow-up, endpoints were recorded in the electronic
case report forms by trained research physicians, and as-
sociated hospital records and discharge letters were col-
lected. Subsequently, a clinical event committee blinded to
the biomarker results reviewed all collected information and
adjudicated primary and secondary endpoints.
The primary endpoint comprised the composite of car-
diac death, cardiac transplantation, left ventricular assist de-
vice implantation, and hospitalisation for the management
of acute or worsened HF.
Cardiac death was defined as death from myocardial
infarction (MI) or other ischaemic heart disease (ICD-
10: I20–I25), death from other heart disease including HF
(I30–I45 and I47–I52), sudden cardiac death (I46), sud-
den death undefined (R96) or unwitnessed or ill-described
death (R98, R99). Hospitalisation for acute or worsened
HF was defined as exacerbation of symptoms typical of
HF, in combination with two of the following: BNP or NT-
proBNP > 3x the upper limit of normal, signs of worsening
HF, such as pulmonary rales, raised jugular venous pres-
sure or peripheral oedema, increased dose or intravenous
administration of diuretics, or administration of positive
inotropic agents.
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Table 1 Baseline characteristics
NYHA class I
(n = 78)
NYHA class II
(n = 116)
NYHA class III/IV
(n = 66)
Total
(n = 263)
Demographics
Age 64 (±11) 68 (±13) 72 (±11) 67 (±13)
Male gender 60 (78) 81 (69) 48 (70) 189 (72)
Caucasian ethnicity 71 (92) 107 (92) 66 (94) 244 (94)
Clinical characteristics
Body mass index kg/m2 28 (±5) 27 (±4) 28 (±4) 28 (±5)
Heart rate, bpm 63 (±10) 68 (±11) 69 (±13) 67 (±12)
SBP, mm Hg 123 (±19) 124 (±20) 120 (±21) 122 (±20)
DBP, mm Hg 75 (±11) 72 (±11) 71 (±10) 72 (±11)
Biomarker level
NT-proBNP (pmol/l) 93 (38–175) 141 (49–583) 225 (120–436) 140 (52–273)
HsTNT (ng/l) 13 (7.8–21) 19 (9.9–37) 24 (16–43) 18 (10–33)
CRP (mg/l) 1.6 (0.6–3.4) 2.3 (1.0–5.3) 2.7 (1.3–4.9) 2.2 (0.9–4.8)
Creatinine (mg/dl) 1.2 (1.0–1.5) 1.1 (1.0–1.4) 1.3 (1.0–1.6) 1.2 (1.0–1.5)
eGFRa (ml/min/1.73 m2) 62 (42–83) 58 (46–78) 53 (38–72) 58 (43–76)
Medical history
CAD 29 (39) 57 (50) 56 (84) 142 (46)
ICD 42 (55) 67 (57) 42 (61) 151 (59)
CRT 20 (26) 40 (34) 18 (26) 78 (30)
CVA 8 (10) 18 (15) 15 (22) 41 (16)
Chronic renal failure 34 (44) 61 (52) 41 (59) 136 (53)
Diabetes mellitus 16 (23) 34 (28) 31 (42) 81 (31)
Hypercholesterolaemia 26 (34) 41 (35) 26 (38) 93 (36)
Hypertension 33 (43) 56 (48) 31 (45) 120 (46)
Intoxications
Alcohol consumption 30 (40) 51 (44) 27 (39) 108 (42)
Ever smoker 58 (75) 79 (68) 48 (70) 185 (71)
Medication use
ACE-i or ARB 75 (96) 109 (94) 61 (88) 245 (93)
Aldosterone antagonist 44 (56) 81 (70) 53 (80) 178 (68)
Diuretic 64 (82) 107 (92) 66 (96) 237 (90)
Beta-blocker 68 (87) 106 (91) 58 (88) 232 (88)
Aspirin 14 (18) 16 (14) 15 (22) 45 (17)
Vitamin K antagonist 59 (77) 88 (78) 53 (77) 200 (77)
Normally distributed continuous variables are presented as mean (± standard deviation). Non-normally distributed continuous variables are ex-
pressed as median (25th–75th percentile). Categorical variables are expressed as count (percentage). Valid percentages are given because of missing
values, thus total counts may vary.
ACE-i angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CAD coronary artery disease, CRP C-reactive protein, CRT car-
diac resynchronisation therapy, CVA cerebrovascular accident, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, HsTNT
high sensitive cardiac troponin T, ICD implantable cardioverter defibrillator, NT-proBNP N-terminal pro-B-type natriuretic peptide, NYHA New
York Heart Association, SBP systolic blood pressure
aeGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
Statistical analysis
Statistical methods are described in detail in the supple-
mental text (online Electronic Supplementary Material). In
brief, we used linear mixed models to assess the associa-
tions between serial biomarker measurements and repeated
assessment of NYHA functional class. Associations be-
tween serial measurements of biomarkers and NYHA class,
and occurrence of the primary endpoint, were examined by
entering the serial measurements as time-varying covari-
ates into extended Cox proportional hazards models. First,
the models were adjusted for age, gender, systolic blood
pressure and estimated glomerular filtration rate (eGFR;
calculated using the Chronic Kidney Disease Epidemiol-
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Table 2 Associations between blood biomarker measurements, NYHA class, and the primary endpoint
Associations between baseline measurements and the primary endpoint
Univariable modelsa Multivariable modelb
HR (95% CI) p HR (95% CI) p
NT-proBNPc 3.10 (1.87–5.13) <0.001 2.37 (1.39–4.02) 0.003
Hs-TnTc 1.94 (1.33–2.84) <0.001 1.50 (0.96–2.33) 0.11
CRPc 1.55 (1.12–2.16) 0.005 1.53 (1.10–2.14) 0.013
NYHA classd 2.22 (1.41–3.50) <0.001 2.14 (1.33–3.45) 0.003
Associations between serial measurements and the primary endpoint
Univariable modelsa Multivariable modelb
HR (95% CI) p HR (95% CI) p
NT-proBNPc 4.02 (2.50–6.47) <0.001 2.86 (1.73–4.73) <0.001
Hs-TnTc 1.95 (1.36–2.77) <0.001 1.26 (0.86–1.84) 0.32
CRPc 2.08 (1.50–2.87) <0.001 1.69 (1.21–2.34) 0.001
NYHA classd 2.80 (1.83–4.28) <0.001 2.33 (1.51–3.62) <0.001
HR hazard ratio, CRP C-reactive protein, Hs-TnT high-sensitive cardiac troponin T, NT-proBNP N-terminal pro-B-type natriuretic peptide,
NYHA New York Heart Association
aIncluding age and gender
bIncluding age, gender, systolic blood pressure and estimated glomerular filtration rate
cHR per standard deviation increase in log transformed level
dHR per 1-step increase
ogy Collaboration (CKD-EPI) equation). Subsequently, all
variables, i. e. NT-proBNP, Hs-TnT, CRP and NYHA func-
tional class, were entered simultaneously into the models to
investigate their independence. We calculated time-depen-
dent C-indices based on the extended Cox models. Analyses
were performed with R Statistical Software and MedCalc.
Results
Study population
A total of 263 patients were included from October 2011 to
June 2013. Baseline characteristics are displayed in Tab. 1.
Mean age was 67 years (SD ± 13), 72% were men, and
73% were in NYHA class I or II. Median duration of HF
at inclusion was 4.6 years (IQR 1.7–9.9). Median baseline
NT-proBNP was 137.3 pmol/l (IQR 51.9–272.9), Hs-TnT
18.0 ng/l (IQR 9.6–33.2) and CRP 2.2 mg/l (IQR 0.9–4.8).
Associations between serial biomarker measurements
and serial assessment of NYHA class
During follow-up, we collected 921 blood samples and
scored NYHA functional class 1,292 times. Of all follow-
up visits, 1,135 took place before the occurrence of the
primary endpoint. During these follow-up visits, 886 blood
samples were drawn (median 3; IQR 2–5 per patient), and
NYHA functional class was scored 1,114 times (median 4;
IQR 2–6 per patient).
Repeatedly measured NT-proBNP and Hs-TnT showed
strong associations with repeatedly assessed NYHA class,
whereas CRP did not (NT-proBNP: β [95% CI]: 1.56
[1.17–2.06]ln(ng/l) increase per point increase in NYHA
class, p = 0.002; HsTNT: β [95%CI]: 1.58 [1.21–2.07],
p = 0.001; CRP: β [95% CI]: 1.22 [0.98–1.53], p = 0.076)
(Tab. 1 of the online Electronic Supplementary Material).
Clinical endpoints
The composite endpoint was reached by 41 patients (16%),
during a median follow-up of 1.0 [0.6–1.4] years: 5 pa-
tients died from a cardiovascular cause, 35 patients were
re-hospitalised for worsened HF and 1 patient underwent
heart transplantation. Of the 35 patients reaching the pri-
mary endpoint because of re-hospitalisation for HF, 16 pa-
tients died eventually during further follow-up, of whom
12 patients died from a cardiovascular cause. Overall all-
cause mortality was 21 (8.0%).
Baseline biomarker measurements and NYHA class and
the primary endpoint
NT-proBNP, Hs-TnT, CRP, and NYHA class all displayed
strong and positive associations with the primary endpoint
(Tab. 2). After multivariable adjustment, NT-proBNP, CRP
and NYHA class remained independently associated with
the primary endpoint, while Hs-TnT lost statistical signif-
icance. Of all the other baseline characteristics, only age
was independently associated with the primary endpoint.
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Fig. 2a–d Temporal evolution of serial biomarker measurements and NYHA class. X-axes display the time that is left until occurrence of the
clinical endpoint
Serial measurements of biomarkers and NYHA class,
and the primary endpoint
Temporal evolutions of serial biomarker measurements and
NYHA class are displayed in Fig. 2. Serially measured
NT-proBNP, Hs-TnT, CRP, and NYHA class all displayed
strong and positive associations with the primary endpoint
(Tab. 2). After multivariable adjustment for all serially mea-
sured variables, NT-proBNP, CRP and NYHA class re-
mained significantly associated with the primary endpoint.
Model performance
The discriminative abilities of the models containing base-
line measurements of NT-proBNP, Hs-TnT, CRP and
NYHA class are shown in the online Electronic Supple-
mentary Material, supplemental Tab. 2, and those of serial
measurements in Tab. 3. All individual serially assessed
C-indices, except for Hs-TnT, were numerically higher
than corresponding baseline C-indices. Adding serial NT-
proBNP to the model containing age, sex, systolic blood
pressure and eGFR and NYHA class provided a substan-
tial increase in C-index from 0.76 (CI 0.66–0.86) to 0.84
(0.74–0.93), although this did not reach statistical sig-
nificance (p = 0.26). Adding serial CRP instead to this
same multivariable model resulted in a C-index of 0.82
(0.72–0.92), p = 0.40. Adding both serial NT-proBNP and
CRP to the multivariable model only resulted in a slight
improvement compared with addition of NT-proBNP only:
0.85 (CI 0.75–0.95), p = 0.20.
Discussion
In this prospective, observational cohort of CHF patients,
repeatedly measured NT-proBNP and Hs-TnT were posi-
tively and significantly associated with repeatedly assessed
NYHA class. Serial assessments of NT-proBNP, CRP and
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Table 3 Discriminative ability
of models containing serial
blood biomarker and NYHA
assessment
Model C-index (CI) P-value
Modela 0.62 (0.52–0.71) NA
Modela + NT-proBNP 0.80 (0.70–0.90) 0.010b
Modela + Hs-TnT 0.72 (0.62–0.82) 0.13b
Modela + CRP 0.76 (0.66–0.85) 0.048b
Modela + NYHA class 0.76 (0.66–0.86) 0.040b
Modela + NYHA class + NT-proBNP 0.84 (0.74–0.93) 0.26c
Modela + NYHA class + Hs-TnT 0.79 (0.69–0.89) 0.67c
Modela + NYHA class + CRP 0.82 (0.72–0.92) 0.40c
Modela + NT-proBNP + CRP 0.82 (0.73–0.92) 0.40c
Modela + NYHA class + NT-proBNP + CRP 0.85 (0.75–0.95) 0.20c
CI confidence interval, CRP C-reactive protein, Hs-TnT high-sensitive cardiac troponin T, NT-proBNP N-ter-
minal pro-B-type natriuretic peptide, NYHA New York Heart Association
aIncluding age, gender, systolic blood pressure and estimated glomerular filtration rate
bP-value compared with modela
cP-value compared with modela + NYHA class
NYHA class were independently associated with adverse
clinical outcome. Repeatedly measured NT-proBNP and
CRP both added individually to serial NYHA class assess-
ments in terms of discriminative ability. However, a model
combining both of these biomarkers with serially scored
NYHA class seemed to have little incremental value over
serial NYHA class assessment combined with only one of
these blood biomarkers. In particular, adding NT-proBNP
only seemed the best suited strategy for monitoring stable
CHF outpatients.
The strengths of the current study include simultaneous
assessment of multiple biomarkers and NYHA class on the
one hand, as well as frequent, repeated assessment of these
properties on the other hand. Combined with clinical fol-
low-up on adverse events, this renders insight into temporal
evolution and manifestation of CHF. On top of that, using
biomarker measurements for monitoring patients with CHF
has the appealing feature of being objective, and thus uni-
form and reproducible.
Serial NT-proBNP and CRP measurements were both in-
dependently associated with the endpoint and adding serial
NT-proBNP and CRP measurements to a model contain-
ing NYHA class assessments greatly increased the C-in-
dex, from 0.76 to 0.85. This increase did not reach sta-
tistical significance, but recently it has been demonstrated
that testing for improvement in prediction performance is
actually redundant if a variable has already been shown
to be an independent risk factor, and that standard test-
ing procedures such as C-indices are very conservative and
thus insensitive to improvements in prediction performance
[20]. Nevertheless, to provide an impression of the mag-
nitude of the incremental prognostic value, we presented
C-indices. Altogether, our results support combining blood
biomarkers with clinical assessment for prognostication in
CHF patients.
While the prognostic value of blood biomarkers for clin-
ical events has been widely investigated, less is currently
known about the association between blood biomarkers and
NYHA class in CHF patients. Only two studies have pre-
viously assessed this association. These studies measured
natriuretic peptide level both at study baseline and at 6 ±
2 weeks of follow-up, and correlated these measurements
with, among others, clinical change as categorised by clin-
icians [17, 18]. Studies performing multiple, repeated mea-
surements of biomarkers and NYHA class over a prolonged
follow-up period, and concomitantly investigating their as-
sociation with clinical endpoints have not yet been per-
formed. Although the NYHA functional classification is
a common and globally used system [1, 4], its biggest dis-
advantage is the non-uniformity in its application by indi-
vidual clinicians. Raphael et al. conducted a study to in-
vestigate consistency in NYHA functional class assessment
and found that inter-observer variability was high, with only
54% concordance between two cardiologists [5]. In this re-
spect, adding biomarker information to clinical patient as-
sessment could be valuable for obtaining a more objective
estimate of patient prognosis.
Limitations
Extended Cox models with time-dependent covariates were
used to analyse the effects of changes in NYHA class and
temporal biomarker patterns on the primary endpoint, be-
cause these models are able to accommodate multiple time-
varying covariates. However, time-dependent Cox models
assume that biomarker levels do not change between mea-
surements [21]. In reality, blood biomarkers are dynamic
and continuously change over time, parallel to the con-
dition of the patient. Therefore, we performed a sensitiv-
ity analysis by means of a joint modelling approach. Joint
models combine a linear mixed-effects model for the serial
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biomarker measurements with a Cox proportional hazards
model for the occurrence of the primary endpoint [21]. We
estimated the individual biomarker trajectories and NYHA
trajectories using separate joint models, then extracted the
fitted trajectories from the joint models, and entered the ex-
tracted trajectories simultaneously into one extended Cox
model. The results of this analysis were materially the same
as those we described in the paper. Furthermore, the ma-
jority of the patient population was in NYHA class I or II,
and thus at relatively low risk. The results and conclusions
should be judged accordingly.
Conclusions
Serial assessments of NT-proBNP and Hs-TnT are posi-
tively associated with NYHA class. Temporal patterns of
NT-proBNP, CRP and NYHA class are independently as-
sociated with adverse clinical outcome. A model contain-
ing these serially measured variables displayed good dis-
criminative ability. However, serially measured CRP had
only little incremental discriminative value compared with
a strategy combining serial assessments of NYHA class and
NT-proBNP. Altogether, our findings underscore the incre-
mental value of biomarkers to NYHA class for monitoring
stable CHF outpatients.
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